Scarica l'app Stockscreener
10.28
3.11%
0.31
Dopo l'orario di chiusura:
10.20
-0.08
-0.78%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.97
Aprire:
$10
Volume 24 ore:
7.40M
Relative Volume:
2.29
Capitalizzazione di mercato:
$1.33B
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-16.58
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
+14.67%
1M Prestazione:
+28.66%
6M Prestazione:
+7.53%
1 anno Prestazione:
-25.67%
Intervallo 1D:
$9.9865
$10.40
Intervallo di 1 settimana:
$8.68
$10.40
Portata 52W:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Confronta NEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.28 | 1.21B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
536.78 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
210.92 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
637.34 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
141.10 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
205.75 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
Is NeoGenomics Inc. stock bottoming outQuarterly Risk Review & Weekly Stock Breakout Alerts - newser.com
Could NeoGenomics' (NEO) MRD Advances Redefine Its Edge in Precision Oncology? - simplywall.st
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last? - Nasdaq
NeoGenomics (NEO): Assessing Valuation Following Recent Share Price Momentum - Yahoo Finance
How NeoGenomics Inc. stock compares to growth peersJuly 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
How hedge fund analytics apply to NeoGenomics Inc. stock2025 Risk Factors & Long-Term Safe Investment Plans - newser.com
Visualizing NeoGenomics Inc. stock with heatmapsQuarterly Profit Report & Real-Time Volume Analysis - newser.com
Published on: 2025-10-15 10:40:44 - newser.com
Is NeoGenomics Inc. stock affected by interest rate hikesQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com
Measuring NeoGenomics Inc.’s beta against major indicesQuarterly Earnings Summary & Reliable Momentum Entry Alerts - newser.com
Will NeoGenomics Inc. stock gain from government policiesTrade Performance Summary & High Win Rate Trade Alerts - newser.com
Earnings visualization tools for NeoGenomics Inc.2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025 - BioSpace
NeoGenomics unveils RaDaR ST at ESMO Congress 2025 - Traders Union
Neogenomics, Inc. to Highlight Radar St Mrd Assay At Esmo Congress 2025 - MarketScreener
How to track smart money flows in NeoGenomics Inc.Bond Market & Capital Efficient Trading Techniques - newser.com
Forecasting NeoGenomics Inc. price range with options dataJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Is NeoGenomics Inc. (NG9) stock good for wealth creation2025 Geopolitical Influence & Growth Focused Entry Reports - newser.com
Volatility clustering patterns for NeoGenomics Inc.July 2025 Levels & Verified Swing Trading Watchlist - newser.com
Published on: 2025-10-13 09:16:58 - newser.com
Regression analysis insights on NeoGenomics Inc. performanceExit Point & AI Driven Stock Movement Reports - newser.com
NeoGenomics rallies after court win in Natera patent dispute - MSN
NeoGenomics unveils Paletrra revolutionizing spatial proteomics - Traders Union
NeoGenomics' (NEO) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
What catalysts could drive NeoGenomics Inc. stock higher2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Volume spikes in NeoGenomics Inc. stock – what they meanJobs Report & Verified Chart Pattern Signals - newser.com
Is NeoGenomics Inc. forming a bottoming baseEarnings Recap Report & Weekly Watchlist for Consistent Profits - newser.com
Is NeoGenomics Inc a good long term investmentMarket Liquidity Analysis & Options Trading Analysis Tools - earlytimes.in
United States Pathological Examination Market Growth & - openPR.com
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 - BioSpace
Press Release: NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 - 富途牛牛
NeoGenomics Inc Stock Analysis and ForecastTrading Volume Surges & Outstanding Portfolio Tips - earlytimes.in
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neogenomics Inc Azioni (NEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zook Anthony P. | Chief Executive Officer |
Aug 06 '25 |
Buy |
5.58 |
17,900 |
99,954 |
38,066 |
| Williams Felicia | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
7,160 |
0 |
7,160 |
| KANOVSKY STEPHEN M | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
52,344 |
| Kelly Michael Aaron | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
44,009 |
| TETRAULT LYNN A. | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
73,652 |
| Floegel Elizabeth | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Gunn Neil | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
28,100 |
| Zook Anthony P. | Chief Executive Officer |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Perez David Brian | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
33,890 |
| Kelly Michael Aaron | Director |
May 27 '25 |
Buy |
7.60 |
5,000 |
38,000 |
5,000 |
0.74%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):